SEC Form 4 · accession 0001179110-17-011284
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ravindra Kumar
Officer — SVP & Chief Scientific Officer
Period of report
Aug 8, 2017
Accepted (ET)
Aug 9, 2017 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 8, 2017 | M | 13,065 | $24.11 | A | 108,392 | D | |
| Common StockF2 | Aug 8, 2017 | S | 13,065 | $35.41 | D | 95,327 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF3 | $24.11 | Aug 8, 2017 | M | 13,065 | D | — | Dec 5, 2023 | Common Stock | 13,065 | 3,624 | D |
Explanation of responses
- F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.84 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.